The platform was acquired from US high technology company Clear Lake Medical Foundation, and will be the foundation of a future development project.
According to CellaVision, the new technology has the potential to develop into an affordable solution for the smaller hospital laboratories. The purchase price payable in installments upon achievement of certain goals will amount to approximately $ 1 million.
“We are excited to acquire this break-through technology that should make it possible to expand our product portfolio, including new products for smaller laboratories presently outside our current target market. Implementation of the new platform will be done in close collaboration with Clear Lake Medical Foundation and begin promptly. We expect, however, that it will take a few years before the first product reaches the market,” says Yvonne Mårtensson, CEO of CellaVision, in a press release.